AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%
BlackBerry Ltd
BlackBerry Ltd (NYSE: BB) provided enterprise and security software to businesses and government across the globe.
On 24 June 2021, BB is due to release its Q1 FY22 results.
Investment Rationale – WATCH at USD 13.82
Risk Assessments
Recent News
7 June 2021: BB partnered with BiTECH Automotive (Wuhu) Co Ltd for building LCD instrument cluster to be installed in the the UNI-K (Changan Automobile's new SUV).
Financial Highlights for the fiscal year ended 28 February 2021 (as on 31 March 2021)
(Source: Company Website)
Share Price Chart
(Analysis done by Kalkine Group)
Conclusion
BB demonstrated weak financial results in FY21. The Company’s QNX automotive software business is likely to remain impacted until early FY22 due to the economic downturn as it continued to adversely affect the automotive software business. Moreover, the Covid-19 disruption can also harm the supply chain and customer demand. Adjacently, volatility in the financial market could also impact the Company’s ability to raise external funds. After reporting losses, the Company also need external funds to pursue growth opportunities. Therefore, the outlook seems gloomy to invest at the current position. The stock made a 52 week High and Low of USD 28.77 and USD 4.37, respectively.
Based on the weak fundamentals, macroeconomic uncertainties, aggravated losses, we have given a “Watch” stance on BlackBerry Ltd at the current price of USD 13.82 (as on 15 June 2021, 12:10 PM ET), while we look forward to reviewing the demand recovery.
AcelRx Pharmaceuticals Inc
AcelRx Pharmaceuticals Inc (Nasdaq: ACRX) is a specialty pharmaceutical entity that is involved in the development and commercialization of DSUVIA® and Zalviso®.
Investment Highlights – SPECULATIVE BUY at USD 1.45
Key Risks
Recent News
20 May 2021: AcelRx announced an investigator-initiated study of DSUVIA® for patients with sickle cell disease.
Q1 FY21 Financial Highlights (for three months ended 31 March 2021, as of 17 May 2021)
(Source: Company website)
Share Price Chart
(Analysis done by Kalkine Group)
Valuation Methodology: EV/Sales Approach (FY21) (Illustrative)
Conclusion
During Q1 FY21, AcelRx showed significant growth in financial results. However, the ultimate impact of the Covid-19 is highly uncertain. Notwithstanding, the Company has a decent liquidity position to navigate through uncertainties and fund its operations. It has 432 formulary approvals as of 30 April 2021. It is also making solid progress in terms of the commercialization of DSUVIA, which can make the Company profitable. The stock made a 52-week High and Low of USD 2.94 and USD 1.01, respectively. On the technical chart, the next important support level is at USD 1.26.
Based on the improved revenue, reduced losses, commercialization progress, supported by the valuation conducted above, we have given a "SPECULATIVE BUY" stance on AcelRx Pharmaceuticals Inc at the current market price of USD 1.45 (as of 15 June 2021, 12:10 PM ET).
*All forecasted figures and Industry Information have been taken from REFINITIV.
*The reference data in this report has been partly sourced from REFINITIV.
*Depending upon the risk tolerance, investors may consider unwinding their positions in a respective stock once the estimated target price is reached or if the price closes below the support level (indicative stop-loss price).